Biotron Limited

Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.